WSJ
24 Jul 2026, 07:24 UTC · 9w ago
Verdict
Headline leans bearish. We score PROV −0.80 across one claim.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Bylvay failed to meet its primary study objective of improving native liver survival rates compared to a placebo.
More negative than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More negative than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 85% of ticker scores this week
The company's drug Bylvay failed to meet the primary objective of a clinical study regarding liver survival rates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
14h ago
+6.7%
Price is moving against the score
$18.37 vs $17.21 close before publication (Jul 23) · not market-adjusted
PROV chart →
